

March 4, 2002

To; All Parties Concerned

Company: Taisho Pharmaceutical Co., Ltd.  
Head Office: 24-1, Takata 3-Chome, Toshima-ku,  
Tokyo  
Representative: Akira Uehara, President  
(First Section of the Tokyo Stock  
Exchange: Ticker Code 4535)  
Contact: Takashi Shibata, Manager of  
Public Relations Section

## **Notification of Treasury Stock Purchase**

Taisho Pharmaceutical hereby announces that at its Board of Directors Meeting held on March 4, 2002, in accordance with Section 3 of the Commercial Code governing the retirement of shares applied under Item 4 of Section 3 of Supplementary Provisions to the Law concerning a partial revision of the Japanese Commercial Code (Law No. 79 promulgated in 2001), it was determined that the Company would carry out the retirement of common stock into its treasury stock fund.

### 1. Details of Stock Purchase

- (1) Type of stock: Taisho par-value common stock
- (2) Amount of stock: 10,000,000 shares (upper limit)  
(2.93% of 340,965,510 shares outstanding)
- (3) Total value of stock: ¥20.0 billion (upper limit)

### 2. Purpose of Stock Purchase

- (1) To provide the Company's shareholders with a profit by raising our capital efficiency and reducing the number of outstanding shares of common stock
- (2) To enable flexible financial administration that responds to business expansion

Notes: Total amount of stock that may be retired under the Articles of Association: 34,000,000  
Number of shares retired since the Articles of Association were established: 4,541,000